Recent Updates
Recently added Catalysts
OSTX Positive Sentiment

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

Friday, May 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: OS Therapies has announced the upcoming release of four articles related to OST-HER2 and osteosarcoma. Notably, they will present 2.5-year overall survival data from their Phase 2b clinical trial at the 2026 ASCO Annual Meeting. The articles cover various aspects of osteosarcoma treatment, including regulatory science and the potential for accelerated approval.
Price reaction · baseline $1.98 (2026-05-28 close) · hit pre-market · 1 other OSTX headline(s) in the window, move may be shared
day 0 close
+8.1%
day 1
-5.6%
day 3 · peak
-9.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • OS Therapies is set to present significant survival data at ASCO 2026.
  • The publication of four articles indicates active research and development.
  • Focus on regulatory flexibility shows commitment to addressing patient needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
3.4%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk

Full Press Release Details

• The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma during the 2026 American Society of Clinical Oncologists (ASCO) Annual Meeting being held from May 28, 2026 to June 2, 2026.

• Looking back to see forward: The future of osteosarcoma treatment Publication Date: December 8, 2025
• Comparative Oncology in Osteosarcoma: leveraging canine disease to drive drug discovery and validation of biomarkers and accelerate the pathway to new therapies Publication Date: February 23, 2026
• Novel regulatory science considerations in osteosarcoma: the imperative for regulatory flexibility to meet critical unmet patient and clinical needs Publication Date: May 21, 2026
• The case for accelerated approval in recurrent osteosarcoma Publication Date: May 29, 2026

Frequently Asked Questions

What data will OS Therapies present at ASCO 2026?

OS Therapies will present 2.5-year overall survival data from their Phase 2b clinical trial.

When will the articles on OST-HER2 be published?

The articles will be published between December 2025 and May 2026.

What is the focus of the articles published by OS Therapies?

The articles cover treatment advancements, regulatory science, and accelerated approval for osteosarcoma.

What is OST-HER2?

OST-HER2 is a therapeutic approach being developed by OS Therapies for osteosarcoma.

ShareAdd on Google
Tags: OSTX osteosarcoma clinical trial ASCO 2026 drug discovery
Last updated: May 29, 2026

Biotech snapshot

Cash runway
$0M liquidity · $2M/mo burn
~0 mo
High dilution risk

Catalyst track record

+25%
best trade around OSTX's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OSTX.

See every catalyst's timing & PoA →